Company overview
Elegen provides ENFINIA™ DNA through its patented cell-free platform, delivering linear DNA up to 7 kb and plasmids up to 19 kb with high complexity and NGS-verified 99.999% per base accuracy. Products ship globally from their U.S. facility in 6-10 business days, supporting vaccine development, cell/gene therapies, and protein expression. The Gen II platform enhances speed, length, and efficiency using microfluidics, AI, and robotics.
ENFINIA™ DNA from Elegen is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include cell-free dna synthesis, gene synthesis, enfinia dna, long dna plasmids, high complexity dna.
Structured facts
- Website
- https://elegenbio.com
- Markets served
- United States & Americas
- Keywords
- cell-free dna synthesis, gene synthesis, enfinia dna, long dna plasmids, high complexity dna
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What DNA products does Elegen offer?
- ENFINIA™ linear DNA up to 7 kb with high complexity, 19 kb plasmids with up to 15 kb inserts, and linear DNA with 130-nucleotide poly(A) tails, all NGS-verified and ready for immediate use without cloning.
- What are Elegen's delivery timelines and shipping details?
- DNA ships in 6-8 business days for standard ENFINIA™ and as fast as 10 business days for 5-15 kb plasmids via partners like IDT, from their Menlo Park/San Carlos, California facility with global delivery.
- What applications does Elegen support?
- High-purity gene synthesis for mRNA vaccines, cell and gene therapies, protein expression, and complex sequences like designer polyketide molecules, accelerating R&D without traditional cloning.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
